When administered intratumorally, Nexavant showed a consistent anti-cancer effect in most subcutaneous tumor models, and combination therapies involving Nexavant and anti-PD-1 antibodies were additive/synergistic in most models. This evidence concerns the gene PDCD1 and cancer.